Table 2. Impact of baseline clinical parameters on NSCLC patients.
| Univariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|
| n | Event | OS (mo) | p value | Hazard ratio | p value | 95% CI | |
| Age, years | |||||||
| >60 | 295 | 238 | 12.0 | 0.136 | |||
| ≤ 60 | 195 | 154 | 14.4 | ||||
| BMI | |||||||
| >22 | 278 | 214 | 14.4 | 0.002 | 0.811 | 0.051 | 0.657–1.001 |
| ≤ 22 | 212 | 178 | 11.1 | ||||
| Sex | |||||||
| Male | 238 | 197 | 11.9 | 0.005 | 0.012 | 0.618–0.943 | |
| Female | 252 | 195 | 15.3 | 0.764 | |||
| DM | |||||||
| Yes | 49 | 46 | 9.3 | 0.015 | 1.172 | 0.332 | 0.851–1.613 |
| No | 441 | 346 | 13.4 | ||||
| Smoking history | |||||||
| Never | 309 | 244 | 14.0 | 0.072 | |||
| Former/current | 181 | 148 | 11.1 | ||||
| Performance status | |||||||
| ECOG 0–2 | 442 | 349 | 13.6 | <0.001 | 0.001 | 1.281–2.520 | |
| ECOG 3–4 | 48 | 43 | 3.7 | 1.797 | |||
| EGFR mutation | |||||||
| Yes | 275 | 198 | 18.6 | <0.001 | 0.569 | <0.001 | 0.458–0.708 |
| No | 215 | 194 | 7.5 | ||||
| Tumor type | |||||||
| ADC | 419 | 327 | 13.4 | 0.009 | 0.840 | 0.780–1.358 | |
| Non-ADC | 71 | 65 | 10.2 | 1.029 | |||
| LMR | |||||||
| >3.1 | 260 | 193 | 18.4 | <0.001 | <0.001 | 1.212–1.837 | |
| ≤3.1 | 208 | 191 | 7.7 | 1.844 | |||
| DLM | |||||||
| Yes | 415 | 324 | 13.6 | <0.001 | 0.01 | 1.092–1.880 | |
| No | 75 | 68 | 8.8 | 1.432 | |||
ADC, adenocarcinoma; BMI, body mass index; DM, diabetes mellitus; DLM, de novo liver metastases; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; LMR, lymphocyte-to-monocyte ratio; mo, months; NSCLC, non-small-cell lung cancer; OS, overall survival.